BR112015023469A2 - toxóide, composições e métodos relacionados - Google Patents
toxóide, composições e métodos relacionadosInfo
- Publication number
- BR112015023469A2 BR112015023469A2 BR112015023469A BR112015023469A BR112015023469A2 BR 112015023469 A2 BR112015023469 A2 BR 112015023469A2 BR 112015023469 A BR112015023469 A BR 112015023469A BR 112015023469 A BR112015023469 A BR 112015023469A BR 112015023469 A2 BR112015023469 A2 BR 112015023469A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- toxoids
- toxins
- toxin
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dermatology (AREA)
Abstract
abstract methods of producing purified clostridial toxin comprising tangential flow filtration, hydrophobic interaction chromatography and anion exchange chromatography are disclosed. these methods provide good yields of c. difficile toxin having a purity of about 90% or greater. highly purified clostridial toxins, toxoids (e.g., prepared by inactivating the toxin as disclosed herein) and compositions comprising these toxins and/or toxoids are also disclosed. methods of using the purified toxins and/or toxoids for example, to elicit an immune response against clostridium (e.g., c. difficile) are also disclosed. tradução do resumo resumo toxóide, composições e métodos relacionados tratam-se de métodos de produção de toxina de clostrídial purificada compreendendo filtração por fluxo tangencial, cromatografia de interação hidrófoba e cromatografia de permuta aniônica. estes métodos proporcionam bons rendimentos de c. difficile toxina com uma pureza de cerca de 90% ou superior. toxinas clostridiais altamente purificadas, toxóides (por exemplo, preparados por inativar a toxina, tal como aqui descrito) e composições compreendendo estas toxinas e / ou toxóides são também revelados. os métodos de utilização das toxinas e / ou toxóides purificados, por exemplo, para induzir uma resposta imune contra clostridium (por exemplo, c. difficile) são também descritos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793376P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/029070 WO2014144594A1 (en) | 2013-03-15 | 2014-03-14 | Toxoid, compositions and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015023469A2 true BR112015023469A2 (pt) | 2017-07-18 |
| BR112015023469A8 BR112015023469A8 (pt) | 2019-12-03 |
Family
ID=50489432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015023469A BR112015023469A8 (pt) | 2013-03-15 | 2014-03-14 | toxóides, composições e métodos relacionados |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160030542A1 (pt) |
| EP (1) | EP2970400A1 (pt) |
| JP (1) | JP2016519671A (pt) |
| KR (1) | KR20150133771A (pt) |
| CN (1) | CN105308066A (pt) |
| AR (1) | AR095668A1 (pt) |
| AU (2) | AU2014228983B2 (pt) |
| BR (1) | BR112015023469A8 (pt) |
| CA (1) | CA2907156A1 (pt) |
| HK (1) | HK1213917A1 (pt) |
| SG (1) | SG11201507578PA (pt) |
| TW (1) | TW201518316A (pt) |
| WO (1) | WO2014144594A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9730994B2 (en) * | 2013-06-14 | 2017-08-15 | Sanofi Pasteur, Inc. | Compositions and methods for immunizing against C. difficile |
| CN108003224A (zh) * | 2017-12-20 | 2018-05-08 | 天康生物股份有限公司 | 一种多杀性巴氏杆菌毒素蛋白的纯化方法 |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071759A (en) * | 1986-05-30 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Army | Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| WO2009012601A1 (en) | 2007-07-26 | 2009-01-29 | Sanofi Pasteur Limited | Antigen-adjuvant compositions and methods |
| CA2699435A1 (en) | 2007-09-14 | 2009-03-19 | Sanofi Pasteur Biologics Co. | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
| GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
-
2014
- 2014-03-14 WO PCT/US2014/029070 patent/WO2014144594A1/en active Application Filing
- 2014-03-14 KR KR1020157029584A patent/KR20150133771A/ko not_active Application Discontinuation
- 2014-03-14 CA CA2907156A patent/CA2907156A1/en not_active Abandoned
- 2014-03-14 CN CN201480021573.0A patent/CN105308066A/zh active Pending
- 2014-03-14 SG SG11201507578PA patent/SG11201507578PA/en unknown
- 2014-03-14 US US14/776,189 patent/US20160030542A1/en not_active Abandoned
- 2014-03-14 BR BR112015023469A patent/BR112015023469A8/pt not_active Application Discontinuation
- 2014-03-14 AU AU2014228983A patent/AU2014228983B2/en not_active Ceased
- 2014-03-14 JP JP2016502977A patent/JP2016519671A/ja active Pending
- 2014-03-14 EP EP14717952.7A patent/EP2970400A1/en not_active Withdrawn
- 2014-03-17 TW TW103110045A patent/TW201518316A/zh unknown
- 2014-03-18 AR ARP140101274A patent/AR095668A1/es unknown
-
2016
- 2016-02-18 HK HK16101839.5A patent/HK1213917A1/zh unknown
-
2018
- 2018-07-04 AU AU2018204879A patent/AU2018204879A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201518316A (zh) | 2015-05-16 |
| AU2014228983A1 (en) | 2015-10-08 |
| WO2014144594A8 (en) | 2014-11-13 |
| SG11201507578PA (en) | 2015-10-29 |
| KR20150133771A (ko) | 2015-11-30 |
| HK1213917A1 (zh) | 2016-07-15 |
| AU2018204879A1 (en) | 2018-07-26 |
| AU2014228983B2 (en) | 2018-04-05 |
| CN105308066A (zh) | 2016-02-03 |
| WO2014144594A1 (en) | 2014-09-18 |
| CA2907156A1 (en) | 2014-09-18 |
| EP2970400A1 (en) | 2016-01-20 |
| BR112015023469A8 (pt) | 2019-12-03 |
| AR095668A1 (es) | 2015-11-04 |
| JP2016519671A (ja) | 2016-07-07 |
| US20160030542A1 (en) | 2016-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501552A1 (en) | Polypeptide-antigen conjugates with non-natural amino acids | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| MX2019005268A (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
| MX351074B (es) | Vacunas contra clostridium difficile que comprenden toxinas recombinantes. | |
| CO7121348A2 (es) | Proteínas de fusión de interleuquina-2 y usos de las mismas | |
| DOP2013000235A (es) | Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae. | |
| MX2016009072A (es) | Fusion de antigenos micobacterianos heterooligomericos. | |
| MX2016003419A (es) | Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico. | |
| BRPI0816790A8 (pt) | Composições farmacêuticas contendo toxóides a e b de clostridium difficile | |
| EA201391183A1 (ru) | Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин | |
| PH12019500989A1 (en) | Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof | |
| MX368142B (es) | Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab. | |
| BR112016011170A8 (pt) | derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica | |
| BR112016016539A2 (pt) | micro-organismos recombinantes enriquecidos com carboidratos | |
| BR112014018732A8 (pt) | Composições imunogênicas contra campylobacter e usos das mesmas | |
| BR112015023469A2 (pt) | toxóide, composições e métodos relacionados | |
| BR112017010718A2 (pt) | polinucleotídeo otimizado por códon para expressão de alto nível de crm197 | |
| IN2012DE00622A (pt) | ||
| BR112015023332A2 (pt) | Toxóide, composições e método relacionados | |
| MX2016002386A (es) | Vacuna bacteriana y metodos para la fabricacion de la misma. | |
| PH12015500095A1 (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| MX2015017257A (es) | Composiciones y metodos de inmunizar contra clostridium difficile. | |
| BR112016017242A2 (pt) | Vetores lentivirais para gerar respostas imunes contra o vírus linfotrópico-t humano do tipo 1 | |
| BR112015032468A2 (pt) | vacina para disenteria suína | |
| BR112019007257A2 (pt) | micro-organismos e métodos para a coprodução de etileno glicol e isobuteno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |